2026-10-14T15:51:20Z https://www.scidb.cn/oai

10.57760/sciencedb.44370 2026-07-31T16:03:14Z

2026-07-31 Impact of Baseline Platelet Count on Complete Remission Rate, Risk of Bleeding Events, and Overall Prognosis in Patients with Newly Diagnosed Acute Myeloid Leukemia: A Single-Center Retrospective Cohort Study doi:10.57760/sciencedb.44370 en Acute myeloid leukemia (AML) is a type of blood cancer that starts in the bone marrow. Platelets are tiny blood cells that help stop bleeding when we are injured. In many patients with AML, platelet counts are very low at the time of diagnosis. Whether this low platelet level at diagnosis carries additional prognostic information independent of the real-time counts during treatment has remained unclear. Our research team studied 356 adults who were newly diagnosed with AML (excluding the subtype called acute promyelocytic leukemia) at a single hospital between 2020 and 2025. We divided the patients into two groups: those with a low platelet count below 50×10⁹/L (218 patients) and those with a normal or high platelet count of 50×10⁹/L or above (138 patients). We then examined three things — whether the patients achieved complete remission after initial chemotherapy, whether they suffered severe bleeding, and how long they survived. We found that the chance of achieving complete remission was similar in both groups. However, patients with low platelet counts at diagnosis were much more likely to experience severe bleeding, and their overall survival was significantly shorter. For every 10×10⁹/L increase in baseline platelet count, the risk of severe bleeding dropped by about 21% and the risk of death within two years dropped by about 7%. These findings remained consistent even after we used statistical methods to balance the two groups. In summary, a simple baseline platelet count below 50×10⁹/L is a useful, inexpensive marker that helps doctors identify AML patients at higher risk of serious bleeding and poorer survival, so that closer monitoring and earlier supportive care can be given. Acute myeloid leukemia; platelet count; bleeding; overall survival; propensity score matching; retrospective cohort study Yaping Li EMBARGO https://creativecommons.org/licenses/by-nc-sa/4.0/ dataset Science Data Bank